Published in Cancer Weekly, August 9th, 1999
Augusto Caraceni, MD, of the National Cancer Institute of Milan, Italy, and his colleagues administered adjuvant gabapentin therapy with positive results to 22 patients with neuropathic cancer pain not fully controlled by opioids ("Gabapentin as an Adjuvant to Opioid Analgesia for Neuropathic Cancer Pain," Journal of Pain and Symptom Management, June 1999;17(6):441-445).
Gabapentin, the researchers explained, may interfere with opioid resistance mechanisms, among other qualities, according to research data (Mao et al., Pain, 1995;62:259-274).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.